Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06328608 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Study acronym: FLY
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 12 sitesv6
  2. Site details revised at 2 of 12 sitesv5
  3. Study sites: 11 to 12v4
  4. Primary completion date: Dec 2027 to Oct 2028 Start date changed from estimate of Feb 2025 to Jul 29, 2025 · Study sites: 12 to 11 · Completion date: Mar 2028 to Apr 2031v3 Show 3 more changesShow less
    • Start date changed from estimate of Feb 2025 to Jul 29, 2025
    • Study sites: 12 to 11
    • Completion date: Mar 2028 to Apr 2031
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Oct 2024 to Feb 2025 · Study sites: 0 to 12v2 Show 2 more changesShow less
    • Start date: Oct 2024 to Feb 2025
    • Study sites: 0 to 12
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Trial Details
NCT Number NCT06328608
Lead Sponsor Chiesi Farmaceutici S.p.A.
Collaborators: ICON plc
Conditions Fabry Disease
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov